首页 » 文章 » 文章详细信息
Journal of Oncology Volume 2019 ,2019-07-14
C-Reactive Protein to Prealbumin Ratio (CPR): A Novel Inflammatory-Nutritional Prognostic Factor for Predicting Cancer-Specific Survival (CSS) and Overall Survival (OS) in Patients with Resectable Esophageal Squamous Cell Carcinoma
Research Article
Ji-Feng Feng 1 , 2 Liang Wang 1 You-Hua Jiang 1 Xun Yang 1 , 2
Show affiliations
DOI:10.1155/2019/4359103
Received 2019-04-02, accepted for publication 2019-06-16, Published 2019-06-16
PDF
摘要

Background. The inflammation and nutrition play an important role in prognosis. A novel index combined with inflammatory and nutritional biomarkers, named C-reactive protein (CRP) to prealbumin (PALB) ratio (CPR), was initially reported to predict the prognosis in resectable esophageal squamous cell carcinoma (ESCC). Patients and Methods. A retrospective study was conducted including 346 resectable ESCC patients. The X-tile program was used to confirm the optimal cut-off value. The Kaplan-Meier methods and Cox regression analyses were performed to analyze the cancer-specific survival (CSS) and overall survival (OS). Results. The optimum cut-off point was 0.03 for CPR. Patients with a high level of CPR (> 0.03) were associated with poor CSS (12.0% vs. 43.0%, P<0.001) and OS (11.2% vs. 40.7%, P<0.001). Multivariate analyses revealed that CPR was an independent predictor in resectable ESCC patients (CSS, P=0.008; OS, P=0.007). Conclusion. This study, to the best of our knowledge, is the first to investigate prognostic role of CPR in patients with ESCC. Our retrospective observations indicate that CPR, with the optimal cut-off value of 0.03, is a useful potential predictor in resectable ESCC patients.

授权许可

Copyright © 2019 Ji-Feng Feng et al. 2019
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

通讯作者

1. Ji-Feng Feng.Department of Thoracic Oncological Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, No.38 Guangji Road, Hangzhou 310022, China, zchospital.com;Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, No. 38 Guangji Road, Zhejiang Province, Hangzhou 310022, China.fengjif@163.com
2. Xun Yang.Department of Thoracic Oncological Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, No.38 Guangji Road, Hangzhou 310022, China, zchospital.com;Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, No. 38 Guangji Road, Zhejiang Province, Hangzhou 310022, China.xunyangzj@sina.com

推荐引用方式

Ji-Feng Feng,Liang Wang,You-Hua Jiang,Xun Yang. C-Reactive Protein to Prealbumin Ratio (CPR): A Novel Inflammatory-Nutritional Prognostic Factor for Predicting Cancer-Specific Survival (CSS) and Overall Survival (OS) in Patients with Resectable Esophageal Squamous Cell Carcinoma. Journal of Oncology ,Vol.2019(2019)

您觉得这篇文章对您有帮助吗?
分享和收藏
0

是否收藏?

参考文献
[1] T. W. Rice, V. W. Rusch, H. Ishwaran, E. H. Blackstone. et al.(2010). Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American joint committee on cancer/international union against cancer staging manuals. Cancer.116(16):3763-3773. DOI: 10.3322/caac.21254.
[2] J. Lu, B. B. X, Z. F. Zheng. (2019). CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial. Gastric Cancer.22:536-545. DOI: 10.3322/caac.21254.
[3] J. P. Geisler, G. C. Linnemeier, A. J. Thomas, K. J. Manahan. et al.(2007). Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer. Gynecologic Oncology.106(1):128-131. DOI: 10.3322/caac.21254.
[4] R. L. Siegel, K. D. Miller, A. Jemal. (2015). Cancer statistics, 2015. CA: A Cancer Journal for Clinicians.65(1):5-29. DOI: 10.3322/caac.21254.
[5] H. Kato, M. Nakajima. (2013). Treatments for esophageal cancer: a review. General Thoracic and Cardiovascular Surgery.61(6):330-335. DOI: 10.3322/caac.21254.
[6] X. Xu, H. Yu, W. Hu, Q. Song. et al.(2015). A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS ONE.10(9). DOI: 10.3322/caac.21254.
[7] U. Zingg, J. Forberger, B. Rajcic, C. Langton. et al.(2010). Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. Journal of Gastrointestinal Surgery.14(3):462-469. DOI: 10.3322/caac.21254.
[8] H. Miyata, M. Yamasaki, Y. Kurokawa, S. Takiguchi. et al.(2011). Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Experimental and Therapeutic Medicine.2(5):879-885. DOI: 10.3322/caac.21254.
[9] T. Kobayashi, K. Oshima, T. Yokobori, A. Idetsu. et al.(2013). Perioperative nutriture in esophageal cancer patients undergoing esophagectomy. Hepato-Gastroenterology.60(126):1311-1316. DOI: 10.3322/caac.21254.
[10] L. Li, L. Dai, X. Wang, Y. Wang. et al.(2017). Predictive value of the C-reactive protein-to-prealbumin ratio in medical ICU patients. Biomarkers in Medicine.11(4):329-337. DOI: 10.3322/caac.21254.
[11] Y. Yang, Q. Shang, Y. Yuan, X. Wu. et al.(2019). Comparison of long-term quality of life in patients with esophageal cancer after ivor-lewis, mckeown, or sweet Esophagectomy. Journal of Gastrointestinal Surgery.23(2):225-231. DOI: 10.3322/caac.21254.
[12] D. P. Raymond, C. W. Seder, C. D. Wright. (2016). Predictors of major morbidity or mortality after resection for esophageal cancer: A society of thoracic surgeons general thoracic surgery database risk adjustment model. The Annals of Thoracic Surgery.102:207-214. DOI: 10.3322/caac.21254.
[13] J. Ferlay, H. R. Shin, F. Bray, D. Forman. et al.(2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer.127(12):2893-2917. DOI: 10.3322/caac.21254.
[14] D. Unal, O. Orhan, C. Eroglu, B. Kaplan. et al.(2013). Prealbumin is a more sensitive marker than albumin to assess the nutritional status in patients undergoing radiotherapy for head and neck cancer. Współczesna Onkologia.3:276-280. DOI: 10.3322/caac.21254.
[15] X. Yang, Y. Huang, J. F. Feng, J. S. Liu. et al.(2015). Prognostic significance of neutrophil-to-lymphocyte ratio in esophageal cancer: a meta-analysis. Onco Targets Therapy.8:789-794. DOI: 10.3322/caac.21254.
[16] L. T. Guerra, A. R. Rosa, R. F. Romani. (2009). Serum transferrin and serum prealbumin as markers of response to nutritional support in patients with esophageal cancer. Nutricion Hospitalaria.24:241-242. DOI: 10.3322/caac.21254.
[17] H. Shimada, Y. Nabeya, S.-I. Okazumi, H. Matsubara. et al.(2003). Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. Journal of Surgical Oncology.83(4):248-252. DOI: 10.3322/caac.21254.
[18] L. Bedenne, P. Michel, O. Bouché, C. Milan. et al.(2007). Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. Journal of Clinical Oncology.25(10):1160-1168. DOI: 10.3322/caac.21254.
[19] T. Shimura, M. Kitagawa, T. Yamada, M. Ebi. et al.(2012). C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Reseach.32(2):491-496. DOI: 10.3322/caac.21254.
[20] K. J. Napier, M. Scheerer, S. Misra. (2014). Esophageal cancer: A review of epidemiology, pathog enesis, staging workup and treatment modalities. World Journal of Gastrointestinal Oncology.6(5):112-120. DOI: 10.3322/caac.21254.
[21] A. Mantovani, P. Allavena, A. Sica, F. Balkwill. et al.(2008). Cancer-related inflammation. Nature.454(7203):436-444. DOI: 10.3322/caac.21254.
[22] M. J. D. Arnal, Á. F. Arenas, Á. L. Arbeloa. (2015). Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World Journal of Gastroenterology.21(26):7933-7943. DOI: 10.3322/caac.21254.
[23] J. Szkandera, M. Stotz, G. Absenger, T. Stojakovic. et al.(2014). Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. British Journal of Cancer.110(1):183-188. DOI: 10.3322/caac.21254.
[24] C. Mariette, L. Dahan, F. Mornex, E. Maillard. et al.(2014). Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: Final analysis of randomized controlled phase III trial FFCD 9901. Journal of Clinical Oncology.32(23):2416-2422. DOI: 10.3322/caac.21254.
[25] K. Gonda, M. Shibata, Y. Sato, M. Washio. et al.(2017). Elevated neutrophil-to-lymphocyte ratio is associated with nutritional impairment, immune suppression, resistance to S-1 plus cisplatin, and poor prognosis in patients with stage IV gastric cancer. Molecular and Clinical Oncology:1073-1078. DOI: 10.3322/caac.21254.
[26] R. L. Camp, M. Dolled-Filhart, D. L. Rimm. (2004). X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clinical Cancer Research.10(21):7252-7259. DOI: 10.3322/caac.21254.
[27] S. C. Wightman, M. C. Posner, M. G. Patti, S. Ganai. et al.(2017). Extremes of body mass index and postoperative complications after esophagectomy. Diseases of the Esophagus.30(5):1-6. DOI: 10.3322/caac.21254.
[28] X. Wei, F. Wang, D. Zhang, M. Qiu. et al.(2015). A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer.15(1, article no 350). DOI: 10.3322/caac.21254.
[29] J. Feng, Q. Chen. (2014). Significance of the prognostic nutritional index in patients with esophageal squamous cell carcinoma. Therapeutics and Clinical Risk Management.10:1-7. DOI: 10.3322/caac.21254.
[30] J. Shapiro, J. J. van Lanschot, M. C. Hulshof. (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet Oncology.16:1090-1098. DOI: 10.3322/caac.21254.
文献评价指标
浏览 5次
下载全文 0次
评分次数 0次
用户评分 0.0分
分享 0次